<< Market Publishers, BioInformant Worldwide partner to promote market research on Internet | Rapid responders in novel behavior treatment for IBS maintain improvement at 3-month follow-up >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Finnish | Ελληνικά | Norsk | Русский | Svenska | Polski

Celera to present on AIDS pandemic, AZT drugs at Computational Molecular Biology Symposium

Published on May 13, 2010 at 5:16 AM · No Comments

In 1985 there was little hope for people with AIDS. Newspapers and television screens were filled with ghastly pictures of emaciated figures dying from a disease that had no cure.

Then a team of scientists at the National Institutes of Health's National Cancer Institute announced it had come up with the first drug to combat AIDS, and related drugs discovered by this group followed. A quarter-century later in the "Age of the Genome," there still is no cure for AIDS, but it is now highly treatable and it has become a chronic, manageable condition. That first drug, AZT, now a generic, remains in one of many combinations in use that form the backbone for a regimen that has been effective at allowing people with the disease to lead fruitful, normal lives.

Samuel Broder was the director of the Clinical Oncology Program of the National Cancer Institute when AZT was successfully tested. He later became NCI director, appointed by President Reagan. Now the chief medical officer at the biotechnology company Celera, Broder will speak about the AIDS pandemic and how AZT and related drugs changed public attitudes toward the disease.

Broder's presentation comes as 17 leading thinkers from academia, business and government - including two Nobel laureates - will convene at Brown University for the Computational Molecular Biology Symposium, which runs from May 3 to 7. During those five days, participants will discuss advances in genomics, a field of research revolving around the wealth of data contained in the genomes of microbes, plants and animals. With the goal of better understanding human development and evolution, disease and behavior, computational biology is booming, evidenced by a burst of new research programs and new start-up companies.

The group also will hold wide-ranging talks on the the legacy of the famous physicist and computer pioneer John von Neumann, and six guests of the University will participate in the John von Neumann Distinguished Lecture Series.

Sponsored by Brown University, the Center for Computational Molecular Biology and the Department of Computer Science, the symposium is free and open to the public. Registration is required. All sessions will be held in the Thomas J. Watson Sr. Center for Information Technology, located on the Brown campus at 115 Waterman St.

Broder's talk is scheduled to begin at 9 a.m. on May 7. It is titled "The Development of Antiretroviral Therapy and Its Impact on the Global HIV-1/AIDS Pandemic: Personal Reflections on a Journey to Treat an 'Untreatable' Virus After 25 Years."

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading